Follow Us:
PARS‑MDP is a sterile, non‑pyrogen lyophilized radiopharmaceutical kit for bone imaging, which, after radiolabeling with Tc‑99m, is used for evaluation of bone conditions via SPECT imaging. The MDP kit is intended solely for diagnostic use and for the preparation of 99mTc‑Medronate.
- Diagnosis and follow‑up of bone metastases from various cancers
- Detection of bone lesions and abnormal bone growth
- Diagnosis of fractures not visible on radiography
- Diagnosis of osteomyelitis (inflammation of bone or bone marrow caused by bacteria, fungi, or viruses)
- Diagnosis of reflex sympathetic dystrophy (a type of regional pain syndrome that causes severe bone pain following trauma)
- Evaluation of infection in hip joint prostheses
- Diagnosis of increased osteoclastic activity (Paget’s disease)
The PARS‑MDP® kit is manufactured under aseptic conditions. After radiolabeling with a specified amount of sterile, non‑pyrogen sodium pertechnetate injection (Na99mTcO₄) — eluted from a 99Mo/99mTc generator — the preparation is ready for intravenous administration. The dose to be used will be prescribed by the physician.
Methylene Diphosphonic Acid (5 mg)
Stannous Chloride Dihydrate
Ascorbic Acid
Sodium Chloride


